ESMO Asia Congress 2022

Abstract 324P

Background

No standard treatment exists for non-small cell lung cancer (NSCLC) with failure of first-line therapies. Combination of antiangiogenic therapy and immune checkpoint inhibitor therapy is reported as an effective antitumor strategy. Anlotinib is a novel multi-target tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling.We aimed to assess the activity and safety of anlotinib combined with immunotherapy as second-line therapy for advanced NSCLC.

Methods

This is a real world study of anlotinib combined with immunotherapy as second-line treatment for advanced NSCLC. Eligible patients were age≥18 years with histopathologically confirmed non-small cell lung cancer, who have failed at first-line of Immunotherapy combined with chemotherapy. Patients received anlotinib (10mg or 12 mg qd, d1-14, 21 days per cycle) combined with immunotherapy (included sintilimab, pembrolizumab, durvalumab or tislelizumab) until disease progression,unacceptable toxicity, or patient withdrawal. The primary end point was objective response rate (ORR) per RECIST1.1.

Results

From May 2020 to present, 14pts aged 52-79 years (median age 66 years) were enrolled. 11 pts (78.6%) were men, 11 pts (78.6%) ECOG PS=0-1, 7pts (50%) had pleural effusion, and 2 pts (14.3%) had brain metastases, 10 pts (71.4%) with other diseases. Among 14 evaluable pts, the ORR and DCR were 28.6% and 92.9%, At the time of data cutoff, the median PFS was 5.7 months, and the median OS were not mature. Adverse events (AEs) occurred in 2 pts (14.3%), No grade 3≥AEs events occurred.

Conclusions

Anlotinib plus immunotherapy as second-line therapy showed a promising efficacy with a favorable toxicity profile for patients with advanced non-small cell lung cancer. We will report more data in the future.